Neuromodulation Devices Market Size was valued at USD 6.58 Billion in 2022. The Neuromodulation Devices market industry is projected to grow from USD 7.33 Billion in 2024 to USD 15.72 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.99% during the forecast period (2024 - 2032).Growing number of health issues brought on by the pandemic and rising prevalence of chronic conditions that are resistant to treatment, these are the key market drivers enhancing the market growth.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
CVRx launched a new Barostim Programmer, the world’s first FDA-approved neuromodulatory device to alleviate the multiple symptoms of heart failure, in July 2022. This second-generation Barostim programmer has a highly contemporary style and operates on a highly improved cellular network that gives 360-degree remote-view access. It also features an advanced user interface, which is very helpful in simplifying IPG programming.
In July 2022, Orchestra BioMed entered into a partnership with Medtronic for cardiac neuromodulation therapy. The collaboration with Medtronic will drive its development of BackBeat CNT (Cardiac Neuromodulation Therapy) up a notch from where it is now, as well as indicate the need for a pacemaker.
SpineX recruited its first patient for Scone Therapy, an advanced trial therapy for spinal neuromodulation, in June 2022. In the future, Spine X intends to use this Scone Neuromodulation device to evaluate how effective and safe this technology would be in treating neurogenic bladder. Additionally, this treatment can potentially address such grave symptoms as reduced capacity of the bladder, sensations of fullness around it and leakage of urine.
Greenbook TMS, Inc. and Neuronetics, Inc. announced a five-year commercial agreement aimed at strengthening their collaborations in April 2022. Greenbrook will be purchasing exclusively its devices for on-label indications from Neuronetics. Meanwhile, Neuronetics will offer joint education and marketing support, negotiated price terms as well as driving increased collaboration between the companies and other benefits. It is expected that this partnership would bring about category awareness creation among MDD patients and their families/friends, improve neuro health care standards, and transform lives.
NeuroSigma announced NeuroSigma Monarch eTNS System granted FDA Breakthrough Device Designation (BDD) for adjunctive use in reducing the frequency of seizures in epileptic patients aged 18 years and above in February 2022. According to NeroSigma, this designation could enable them to deliver these patients with newer technologies earlier that would facilitate their recovery from the disease.
LivaNova’s OSPREY clinical study had its first patient implanted in February 2022. LivaNova has initiated a randomized controlled clinical trial whose aim is to assess the efficacy and safety of the LivaNova aura6000 System, which is an implantable hypoglossal neurostimulator designed for moderate-severe obstructive sleep apnea (OSA) patients. According to LivaNova, such study marks a major breakthrough into finding effective and new therapies for OSA global patients.
In January 2022, Nevro Corporation announced UnitedHealthcare Coverage for its high-frequency 10 kHz neuromodulation therapy to treat painful diabetic neuropathy (PDN). The coverage decision from UnitedHealthcare will help more PDN patients access its high-frequency 10 kHz therapy.
Market CAGR for neuromodulation devices is being driven by the rising number of health problems. Anti-seizure medications don't always keep epilepsy under control. These medications occasionally have serious side effects that are problematic. Or, it might not be possible to control seizures using a variety of medications together. Neuromodulation devices may be a possibility if medications and epilepsy surgery are not an option or haven't effectively reduced seizures. Small electrical currents are delivered to the brain using neuromodulation devices. Simply put, these electrical currents work to suppress the early aberrant electrical signals that cause seizures, so preventing seizures from occurring.
Additionally, a sizable fraction of patients with chronic diseases, such as persistent back pain, depression, epilepsy, and sleep apnea, among others, are displaying resistance to medications and medication. Treatment progression is slow, and there are limited or delayed results, which are clear signs of resistance. Medical professionals' attention has shifted as a result, and the market trends for neuromodulation devices are being driven by the use of neurostimulation techniques to treat chronic illnesses. Each year, an estimated 50 million Americans experience chronic pain, in addition to about 19 million experiencing high impact chronic pains, according to information CDC (Centres for Disease Control and Prevention) information. Neuromodulation is frequently preferred by patients over medication therapy when treating neurological illnesses. The reason for this is that few patients are aware that alternative surgical procedures using neuromodulation devices are available. There are surgeons in various nations who exhibit this same lack of awareness.
The cost of treating individuals for chronic disorders like epilepsy, depression that is resistant to therapy and other similar issues places a significant financial strain on nations. Healthcare professionals now favor neurostimulation techniques over drugs because of the limited pharmacological results that they may achieve in treating these disorders. The procedures that are most frequently used are spinal cord stimulation of any kind, deep brain stimulation, vague stimulation of the nerves, sacral nerve stimulation, and others. For instance, many people worldwide still do not receive therapy for overactive bladder (OAB) syndrome because they are not aware of efficient choices, such as sacral nerve stimulation. Thus, throughout the projected period, the expansion of this market is anticipated to be constrained by the lack of knowledge about the benefits of employing biomaterials or neuromodulation devices to treat a variety of neurological conditions.
For instance, neurological illnesses are thought to affect a billion people worldwide, and 6.8 million of them pass away each year (Source: WHO). Nerve damage is greatly influenced by sports-related accidents. There are between 1.6 million and 3.8 million concussions among athletes each year, according to the Brain Injury Research Institute. Patients with such neurological illnesses and nerve injuries are treated using neuromodulation procedures such as transcutaneous electrical nerve stimulation, deep brain stimulation, and spinal cord stimulation. Thus, result in driving the Neuromodulation Devices market revenue.
The Neuromodulation Devices market segmentation, based on type includes Internal, External. The internal segment dominated the market. An increase in the number of people afflicted with heart-related illnesses, despair, and other headache types. Due to their use of non-invasive or minimally invasive technology, neuromodulation devices are essential in the treatment of chronic pain.
The Neuromodulation Devices market segmentation, based on Application, includes SCS, DBS, VNS, SNS, GES, TENS, and TMS. The SCS category generated the most income in 2022. Devices used in medicine to relieve chronic pain include spinal cord stimulators. A wide variety of pain kinds, as well as pain from various diseases or origins, can be treated by these devices. Spinal cord stimulators can alleviate pain that hasn't responded to conventional forms of treatment; however there are disadvantages and potential consequences.
The Neuromodulation Devices market segmentation, based on Biomaterial, includes Metallic, Polymeric, and Ceramic. The metallic category generated the most income in the year 2022, because of the expansion and developments in research and development for neuromodulation technologies. Over the course of the prediction, the section is also anticipated to hold its position. According to three categories, the market is divided on the kind of biomaterial: polymeric, metallic, and ceramic biomaterials.
The Neuromodulation Devices market segmentation, based on End-User, includes Hospitals, Clinics, and Homecare. The hospitals category generated the most income in 2022. Neurological diseases patients can have implanted device therapy and neuromodulation surgery in hospitals. Spinal cord stimulation therapy for patients with neurological diseases is the most common neuromodulation therapy offered by hospitals. Given that they provide patients with a more practical, effective, and affordable option to neurological outpatient procedures, ambulatory surgical centers have revolutionized the outpatient experience.
Figure1: Neuromodulation Devices Market, by End-User, 2023 & 2032 (USD Billion)
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American Neuromodulation Devices market area will dominate this market. The market is expanding in North America as a result of factors including an increase in the number of patients with neurological disorders, which is driving up demand for neuromodulation devices, increased market player competition, and significant investment in research and development to create new therapeutic options.
Further, the major countries studied in the market report are The US, Germany, Canada, France, the United Kingdom, Italy, Spain, Australia, South Korea, and Brazil.
Figure2: NEUROMODULATION DEVICES MARKET SHARE BY REGION 2022 (USD Billion)
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Europe Neuromodulation Devices market accounts for the second-largest market share. The market for these devices is being fueled by a strong healthcare infrastructure together with an increase in non-invasive device approvals in the area. Further, the German Neuromodulation Devices market held the largest market share, and the UK Neuromodulation Devices market was the fastest growing market in the European region
The Asia-Pacific Neuromodulation Devices Market is expected to grow at the fastest CAGR from 2024 to 2032. This is because the frequency of neurological illnesses is increasing, the healthcare system is expanding quickly, government support is growing, and there are more startups in this area. Moreover, China’s Neuromodulation Devices market held the largest market share, and the Indian Neuromodulation Devices market was the Asia-Pacific region's fastest-growing market.
Neuromodulation Devices Key Market Players& Competitive Insights
Leading market players are paying a large sum of money on research and development in order to expand their product lines, which will help the Neuromodulation Devices market, grow even more. Additionally, market participants are engaging in a range of strategic initiatives to increase their worldwide reach, with important market developments such as the introduction of new products, contracts, mergers and acquisitions, increased investments, and cooperation with other organizations. To grow and endure in an increasingly competitive and challenging market environment, Neuromodulation Devicesindustry must provide affordable options.
One of the main business strategies employed by manufacturers is to produce locally to reduce operational expenses in the Neuromodulation Devices industry to benefit clients and increase the market sector. In recent years, the Neuromodulation Devices industry has offered some of the most significant advantages to medical industries. Major players in the Neuromodulation Devices market, including Nevro Corporation (U.S.), LivaNova PLC (UK), EnteroMedics Inc (US), Neuronetics Inc. (US), Cyberonics Inc. (US), Jude Medical Inc. (U.S.), Accellent (US), DynaMD (US), and others, invest in operations for research and development in an effort to improve market demand.
LivaNova, PLC is an American medical device company it has its UK headquarters there. Devices for heart surgery and neuromodulation are created by the business. Cyberonics, Inc. of Houston, Texas, and Sorin S.p.a. of Milan, Italy, merged to form the corporation in 2015 for a total of $2.7 billion. On the NASDAQ, the company's stock is listed under the symbol "LIVN." In 2020, to include measurements of depression in its RECOVER clinical study, LivaNova Plc (UK) and Verily (US), an Alphabet firm, entered into research collaboration. The study evaluates the efficacy of vagus nerve stimulation therapy (VNS) for DTD.
Boston Scientific Corporation ("BSC"), incorporated in Delaware, is a biomedical/biotechnology engineering company and a producer of medical devices used in interventional medical specialties, such as interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology, and gynaecology. Boston Scientific is well-known for creating the Taxus Stent, a drug-eluting stent that is used to unblock blocked arteries. In 2019, the business declared that it would increase its electrophysiology and heart product portfolios by acquiring Baylis Medical Company Inc. for $1.75 billion.
Key Companies in the Neuromodulation Devices market include
August 2022:Abbott introduced its brand-new Proclaim Plus SCS system to boost the effectiveness of its neuromodulation treatments. The BurstDR stimulation principle, which mimics the brain's natural patterns to offer pain relief therapy, served as the foundation for the system's design. Furthermore, to present, almost 87% of patients worldwide have chosen to use this technique for using the BurstDR stimulation approach.
July 2022:Orchestra BackBeat CNT, a highly sophisticated cardiac neuromodulation therapy, was created by collaboration between BioMed and Medtronic. It is combined with a number of antihypertensive drugs and is designed in a way that it operates automatically without depending on patient compliance. Furthermore, it can be simply modified to work with pacemakers and other cardiac rhythm control devices utilizing standard implant and lead installation techniques.
July 2021:Helius Medical Technologies, Inc. gained approval from the US Food and Drug Administration. For its PoNSTM, this delivers electrical pulses to the tongue for use in conjunction with physical therapy as a short-term treatment for patients with mild to moderate walking (gait) issues.
Internal
External
SCS
DBS
VNS
SNS
GES
TENS
TMS
Metallic
Polymeric
Ceramic
Hospitals
Clinics
Homecare
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Australia
Rest of Asia-Pacific
Rest of the World
Middle East
Africa
Latin America
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 6.58 Billion |
| Market Size 2024 | USD 7.33 Billion |
| Market Size2032 | USD 15.72 Billion |
| Compound Annual Growth Rate (CAGR) | 9.99% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Application, Biomaterial, End-User, and Region |
| Geographies Covered | North America, Europe, AsiaPacific, and the Rest of the World |
| Countries Covered | The US, Germany, Canada, France, the United Kingdom, Italy, Spain, Australia, South Korea, and Brazil |
| Key Companies Profiled | Â Nevro Corporation (U.S.), LivaNova PLC (UK), EnteroMedics Inc (US), Neuronetics Inc. (US), Cyberonics Inc. (US), Jude Medical Inc. (U.S.), Accellent (US), DynaMD (US) |
| Key Market Opportunities | Growing amount of health issues brought on by the pandemic |
| Key Market Dynamics | Demand for neuromodulation devices will increase due to the rising prevalence of chronic conditions that are resistant to treatment |
Frequently Asked Questions (FAQ) :
The size of the market for neuromodulation devices was estimated at USD 6.58 Billion in 2023.
The expected growth rate for the worldwide market is CAGR of 9.99% during the forecast period, 2024-2032.
The biggest share of the worldwide market was held by North America.
The key players in the market are Nevro Corporation (U.S.), LivaNova PLC (UK), EnteroMedics Inc (US), Neuronetics Inc. (US), Cyberonics Inc. (US), Jude Medical Inc. (U.S.), Accellent (US), DynaMD (US).
The Internal category dominated the market in 2022.
The SCS had the largest share in the market.
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
